These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27416070)

  • 21. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
    Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
    Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantification of plasma EGFR mutations in patients with lung cancers: Comparison of the performance of ARMS-Plus and droplet digital PCR.
    Wang L; Guo Q; Yu W; Qiao L; Zhao M; Zhang C; Hu X; Yang G; Xiong L; Lou J
    Lung Cancer; 2017 Dec; 114():31-37. PubMed ID: 29173762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
    Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
    Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
    Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive profiling and quantitation of oncogenic mutations in non small-cell lung carcinoma using single molecule amplification and re-sequencing technology.
    Zhang S; Xia B; Jiang H; Wang L; Xu R; Shi Y; Zhang J; Xu M; Cram DS; Ma S
    Oncotarget; 2016 Aug; 7(31):50477-50489. PubMed ID: 27409166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Novel Multiplex Droplet Digital PCR Assay to Identify and Quantify KRAS Mutations in Clinical Specimens.
    Alcaide M; Cheung M; Bushell K; Arthur SE; Wong HL; Karasinska J; Renouf D; Schaeffer DF; McNamara S; Tertre MCD; Batist G; Kennecke HF; Karsan A; Morin RD
    J Mol Diagn; 2019 Mar; 21(2):214-227. PubMed ID: 30472330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.
    Jin G; Kim MJ; Jeon HS; Choi JE; Kim DS; Lee EB; Cha SI; Yoon GS; Kim CH; Jung TH; Park JY
    Lung Cancer; 2010 Sep; 69(3):279-83. PubMed ID: 20018398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of EGFR signaling pathway somatic DNA mutations derived from peripheral blood and corresponding tumor tissue of patients with advanced non-small-cell lung cancer using liquidchip technology.
    Zhang H; Liu D; Li S; Zheng Y; Yang X; Li X; Zhang Q; Qin N; Lu J; Ren-Heidenreich L; Yang H; Wu Y; Zhang X; Nong J; Sun Y; Zhang S
    J Mol Diagn; 2013 Nov; 15(6):819-26. PubMed ID: 23988622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative and sensitive detection of rare mutations using droplet-based microfluidics.
    Pekin D; Skhiri Y; Baret JC; Le Corre D; Mazutis L; Salem CB; Millot F; El Harrak A; Hutchison JB; Larson JW; Link DR; Laurent-Puig P; Griffiths AD; Taly V
    Lab Chip; 2011 Jul; 11(13):2156-66. PubMed ID: 21594292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.
    Shepherd FA; Lacas B; Le Teuff G; Hainaut P; Jänne PA; Pignon JP; Le Chevalier T; Seymour L; Douillard JY; Graziano S; Brambilla E; Pirker R; Filipits M; Kratzke R; Soria JC; Tsao MS;
    J Clin Oncol; 2017 Jun; 35(18):2018-2027. PubMed ID: 28453411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.
    Malapelle U; Mayo-de-Las-Casas C; Molina-Vila MA; Rosell R; Savic S; Bihl M; Bubendorf L; Salto-Tellez M; de Biase D; Tallini G; Hwang DH; Sholl LM; Luthra R; Weynand B; Vander Borght S; Missiaglia E; Bongiovanni M; Stieber D; Vielh P; Schmitt F; Rappa A; Barberis M; Pepe F; Pisapia P; Serra N; Vigliar E; Bellevicine C; Fassan M; Rugge M; de Andrea CE; Lozano MD; Basolo F; Fontanini G; Nikiforov YE; Kamel-Reid S; da Cunha Santos G; Nikiforova MN; Roy-Chowdhuri S; Troncone G;
    Cancer Cytopathol; 2017 Aug; 125(8):615-626. PubMed ID: 28475299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosing peripheral lung cancer: the additional value of the Ras-association domain family 1A gene methylation and Kirsten rat sarcoma 2 viral oncogene homolog mutation analyses in washings in nondiagnostic bronchoscopy.
    van der Drift MA; Prinsen CFM; Knuiman GJ; Janssen JP; Dekhuijzen PNR; Thunnissen FBJM
    Chest; 2012 Jan; 141(1):169-175. PubMed ID: 21700687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy.
    Yamaguchi F; Kugawa S; Tateno H; Kokubu F; Fukuchi K
    Lung Cancer; 2012 Dec; 78(3):201-6. PubMed ID: 23026641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimisation of robust singleplex and multiplex droplet digital PCR assays for high confidence mutation detection in circulating tumour DNA.
    Rowlands V; Rutkowski AJ; Meuser E; Carr TH; Harrington EA; Barrett JC
    Sci Rep; 2019 Sep; 9(1):12620. PubMed ID: 31477768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of EGFR mutation in plasma using multiplex allele-specific PCR (MAS-PCR) and surface enhanced Raman spectroscopy.
    Li X; Yang T; Li CS; Wang D; Song Y; Jin L
    Sci Rep; 2017 Jul; 7(1):4771. PubMed ID: 28684733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.
    Kosaka T; Yatabe Y; Onozato R; Kuwano H; Mitsudomi T
    J Thorac Oncol; 2009 Jan; 4(1):22-9. PubMed ID: 19096302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis.
    Fassina A; Gazziero A; Zardo D; Corradin M; Aldighieri E; Rossi GP
    J Clin Pathol; 2009 Dec; 62(12):1096-102. PubMed ID: 19640859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the quantification of KRAS mutations by digital PCR and E-ice-COLD-PCR in circulating-cell-free DNA from metastatic colorectal cancer patients.
    Sefrioui D; Mauger F; Leclere L; Beaussire L; Di Fiore F; Deleuze JF; Sarafan-Vasseur N; Tost J
    Clin Chim Acta; 2017 Feb; 465():1-4. PubMed ID: 27940131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.
    Alegre E; Fusco JP; Restituto P; Salas-Benito D; Rodríguez-Ruiz ME; Andueza MP; Pajares MJ; Patiño-García A; Pio R; Lozano MD; Gúrpide A; Lopez-Picazo JM; Gil-Bazo I; Perez-Gracia JL; Gonzalez A
    Tumour Biol; 2016 Oct; 37(10):13687-13694. PubMed ID: 27473086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical implications of the concentration and EGFR/KRAS mutations of plasma cell free DNA of patients with lung cancer and esophageal cancer].
    Zhang R; Li Y; Chen Y; Liu X; Wang Z; Sun H; Zheng Y; Ding Z; Lan L; Li M; Qin J; Chen X
    Zhonghua Yi Xue Za Zhi; 2015 Dec; 95(47):3839-42. PubMed ID: 27337801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.